1.86
price down icon5.10%   -0.10
after-market アフターアワーズ: 1.87 0.01 +0.54%
loading
前日終値:
$1.96
開ける:
$1.95
24時間の取引高:
903.23K
Relative Volume:
0.78
時価総額:
$42.19M
収益:
$151.12M
当期純損益:
$-194.97M
株価収益率:
-0.1233
EPS:
-15.0871
ネットキャッシュフロー:
$-59.11M
1週間 パフォーマンス:
+2.76%
1か月 パフォーマンス:
-74.90%
6か月 パフォーマンス:
-81.53%
1年 パフォーマンス:
-70.48%
1日の値動き範囲:
Value
$1.83
$1.96
1週間の範囲:
Value
$1.82
$2.0153
52週間の値動き範囲:
Value
$1.79
$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1033)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
228
Name
Twitter
@Karyopharm
Name
次回の収益日
2026-08-13
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KPTI icon
KPTI
Karyopharm Therapeutics Inc
1.86 41.28M 151.12M -194.97M -59.11M -15.09
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
547.59 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
828.50 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,011.11 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
138.89 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
211.58 45.38B 742.00K -1.37B -1.07B -7.0731

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-10 開始されました Rodman & Renshaw Buy
2026-02-05 開始されました Cantor Fitzgerald Overweight
2025-10-13 アップグレード H.C. Wainwright Neutral → Buy
2025-07-16 ダウングレード H.C. Wainwright Buy → Neutral
2025-07-11 再開されました H.C. Wainwright Buy
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
Aug 21, 2026

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance

Aug 21, 2026
pulisher
Aug 20, 2026

Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey

Aug 20, 2026
pulisher
Aug 20, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - YCharts

Aug 20, 2026
pulisher
Aug 20, 2026

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com

Aug 20, 2026
pulisher
Aug 19, 2026

KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView

Aug 19, 2026
pulisher
Aug 18, 2026

Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits

Aug 18, 2026
pulisher
Aug 16, 2026

Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st

Aug 16, 2026
pulisher
Aug 14, 2026

RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

KPTI|Karyopharm Therapeutics Inc|Price:2.015|Chg%:+0.025 - TradingKey

Aug 14, 2026
pulisher
Aug 14, 2026

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey

Aug 14, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics has cash to last only into next month - The Business Journals

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Q2 2026 slides: myelofibrosis data shines amid cash crunch - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

KPTI: Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

Earnings call transcript: Karyopharm Q2 2026 loss widens as cash pressure mounts - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) 2026-08-13 - Seeking Alpha

Aug 13, 2026
pulisher
Aug 13, 2026

Form 8K Karyopharm Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

Is Karyopharm Therapeutics Inc (KPTI) Undervalued at 64.1%? Q2 E - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. Q2 2026: Revenue $33.4M, Net loss $67M, EPS $(2.32) — 10-Q Summary - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics: Q2 Earnings Snapshot - Barchart.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Reports $33.4 Million Q2 Revenue and $67 Million Net Loss - Quiver Quantitative

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - Karyopharm

Aug 13, 2026
pulisher
Aug 13, 2026

BRIEF-Karyopharm Therapeutics Q2 Net Income USD -67.023 Million - TradingView

Aug 13, 2026
pulisher
Aug 12, 2026

Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake - Stock Titan

Aug 12, 2026
pulisher
Aug 12, 2026

Karyopharm Therapeutics Inc Stock Short Interest Rises to 33.51% - Quiver Quantitative

Aug 12, 2026
pulisher
Aug 11, 2026

Goldman Sachs Group (KPTI) discloses 6.3% beneficial stake in Karyopharm - Stock Titan

Aug 11, 2026
pulisher
Aug 11, 2026

Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Aug 11, 2026
pulisher
Aug 10, 2026

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Karyopharm

Aug 10, 2026
pulisher
Aug 10, 2026

Karyopharm’s Aug. 13 results call will include slides online - Stock Titan

Aug 10, 2026
pulisher
Aug 10, 2026

Karyopharm Therapeutics (KPTI) Drops 7.6% to $1.96, Testing Key Support at $1.86Mutual Fund Flow - vinanet.vn

Aug 10, 2026
pulisher
Aug 06, 2026

Myelofibrosis Combo Advances as Karyopharm Preps August sNDA - Streetwise Reports

Aug 06, 2026
pulisher
Aug 04, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC) and Karyopharm Therapeutics (KPTI) - The Globe and Mail

Aug 04, 2026
pulisher
Aug 03, 2026

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm

Aug 03, 2026
pulisher
Aug 03, 2026

Weekly Recap: XPORT-EC-042 misses PFS endpoint and SENTRY sNDA reports SVR35 - TradingView

Aug 03, 2026
pulisher
Aug 02, 2026

KPTI Stock Crashes As Trial Failure Triggers Legal Scrutiny - StocksToTrade

Aug 02, 2026
pulisher
Aug 01, 2026

KPTI Stock Collapses As Trial Failure Triggers Downgrades And Legal Scrutiny - StocksToTrade

Aug 01, 2026
pulisher
Jul 31, 2026

Low coffers, failed endometrial cancer trial: Karyopharm down 72% - bioworld.com

Jul 31, 2026
pulisher
Jul 31, 2026

Jefferies Initiates Karyopharm Therapeutics(KPTI.US) With Buy Rating, Announces Target Price $11 - moomoo.com

Jul 31, 2026

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$123.98
price up icon 0.00%
$61.33
price up icon 0.03%
$112.82
price down icon 3.22%
$236.01
price down icon 0.09%
ONC ONC
$371.98
price down icon 0.66%
$211.58
price up icon 1.01%
大文字化:     |  ボリューム (24 時間):